Related Experiment Video

Updated: Jul 12, 2025

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

637

Comparison between the ECG Outcomes of Metoprolol and Bisoprolol

Ahmad Abdulrahman Almeman1, Yousef Obaid Alharbi2, Abdulaziz Sulaiman Alwahhabi1,3

  • 1Department of Pharmacology, College of Medicine, Prince Sultan Cardiac Center, Qassim University, Buraydah, Qassim, Saudi Arabia.

Cardiovascular & Hematological Agents in Medicinal Chemistry
|November 1, 2023
PubMed

Insights

Metoprolol and bisoprolol, essential beta-blockers for cardiovascular diseases, showed no significant differences in electrocardiogram (ECG) outcomes in this study. Further research is needed to confirm these findings on ECG changes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are crucial for managing cardiovascular diseases like heart failure and myocardial infarction.
  • Diurnal variations exist in beta-blocker efficacy due to pharmacokinetic, pharmacodynamic, and pharmacogenetic differences.

Purpose of the Study:

  • To compare the electrocardiogram (ECG) outcomes of metoprolol and bisoprolol.
  • To assess potential differences in ECG parameters between these two beta-blocker subgroups.

Main Methods:

  • A retrospective cross-sectional study involving 404 patients (204 metoprolol, 200 bisoprolol).
  • Data collected from medical records including demographics, medical history, and treatment history.
  • Analysis of the most recent electrocardiogram (ECG) records.

Main Results:

  • No significant differences were observed in baseline characteristics, age, or sex between the metoprolol and bisoprolol groups.
  • All electrocardiogram (ECG) readings, including PR interval, QTc interval, and ventricular rate, showed no significant differences between the two groups.

Conclusions:

  • Metoprolol and bisoprolol demonstrated comparable effects on ECG parameters in this study.
  • Further investigation is warranted to validate these findings and explore potential nuances in beta-blocker effects.
Abstract

Keywords:
Beta-blockersECGbisoprololcardiovascular diseasesmetoprololpharmacogenetics.

More Related Videos

Electrocardiogram Recordings in Anesthetized Mice using Lead II04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

12.9K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
493
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
701
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
864
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
632
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
751